IMPORTANT NOTE: You may submit your article only through our online submission systemSubmit your manuscript
  • Slider Image

Reviews 2005-2017

Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas. D. MORIS, C. DAMASKOS, E. SPARTALIS, A. PAPALAMPROS, S. VERNADAKIS, D. DIMITROULIS, J. GRINIATSOS, E. FELEKOURAS, N. NIKITEAS (Columbus, OH, USA; Athens, Greece; Riyadh, Kingdom of Saudi Arabia). Anticancer Res 37:2185-2194,2017.
Implications of Different Cancer Stem Cell Phenotypes in Breast Cancer. A.D.C. PAULA, C. LOPES (Porto, Portugal). Anticancer Res 37:2173-2183,2017.
The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma. P.P. SORDILLO, L.A. SORDILLO, L. HELSON (Quakertown, PA; New York, NY, USA). Anticancer Res 37:2159-2171,2017.
Antitumor and Cancer-preventative Function of Fucoxanthin: A Marine Carotenoid. Y. SATOMI (Suzuka, Japan). Anticancer Res 37:1557-1562, 2017.
Acute Graft Versus Host Disease: A Comprehensive Review. S. NASSEREDDINE, H. RAFEI, E. ELBAHESH, I. TABBARA (Washington, DC; Huntsville, AL, USA). Anticancer Res 37:1547-1555, 2017.
Synchronous Endometrial and Ovarian Cancer in Young Women: Case Report and Review of the Literature. A. DOGAN, B. SCHULTHEIS, G.A. REZNICZEK, Z. HILAL, C. CETIN, G. HÄUSLER, C.B. TEMPFER (Bochum, Germany; Mauerbach, Austria). Anticancer Res 37:969-978, 2017.
The role of IL-7 in Immunity and Cancer. J. LIN, Z. ZHU, H. XIAO, M.R. WAKEFIELD, V.A. DING, Q. BAI, Y. FANG (Des Moines, IA; Columbia, MO, USA; Chenzhou, PR China). Anticancer Res 37:963-967, 2017.
Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. I. MARINELLI, A. GUIDO, L. FUCCIO, A. FARIOLI, V. PANNI, L. GIACCHERINI, A. ARCELLI, G. ERCOLANI, G. BRANDI, S. CAMMELLI, A. GALUPPI, G. MACCHIA, R. FRAKULLI, G.C. MATTIUCCI, F. CELLINI, M. BUWENGE, M. RENZULLI, F. DEODATO, S. CILLA, V. VALENTINI, V. TOMBOLINI, R. GOLFIERI, A.G. MORGANTI (Rome; Bologna; Campobasso, Italy). Anticancer Res 37:955-961, 2017.
Possible Therapeutic Effects of Ozone Mixture on Hypoxia in Tumor Development. M. LUONGO, A.L. BRIGIDA, L. MASCOLO, G. GAUDINO (Naples, Italy). Anticancer Res 37:425-435, 2017.
Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights. A. FANDELLA, V. SCATTONI, A. GALOSI, P. PEPE, M. FIORENTINO, C. GAUDIANO, M. GIAMPAOLI, R. GUNELLI, P. MARTINO, V. MONTANARO, R. MONTIRONI, T. PIERANGELI, A. STABILE, A. BERTACCINI (Treviso; Milan; Ancona; Catania; Bologna; Forlì; Bari; Naples, Italy). Anticancer Res 37:413-424, 2017.
Potential Predictive Role of MicroRNAs in the Neoadjuvant Treatment of Esophageal Cancer. D. VRANA, M. MATZENAUER, R. AUJESKY, R. VRBA, C. NEORAL, B. MELICHAR, P. SOUČEK (Olomouc; Prague, Czech Republic). Anticancer Res 37:403-412, 2017.
The Evolving Role of Local Treatments for HCC in the Third Millennium. P. MAGISTRI, G. TARANTINO, R. BALLARIN, M. BERRETTA, Α. PECCHI, G. RAMACCIATO, F. DI BENEDETTO (Modena; Rome; Aviano, Italy). Anticancer Res 37:389-401, 2017.
Immune-based Therapies for Non-small Cell Lung Cancer. H. RAFEI, E. EL-BAHESH, A. FINIANOS, S. NASSEREDDINE, I. TABBARA (Washington, DC; Huntsville, AL, USA; Jounieh, Lebanon). Anticancer Res 37:377-387, 2017.
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. C. DAMASKOS, S. VALSAMI, M. KONTOS, E. SPARTALIS, T. KALAMPOKAS, E. KALAMPOKAS, A. ATHANASIOU, D. MORIS, A. DASKALOPOULOU, S. DAVAKIS, G. TSOUROUFLIS, K. KONTZOGLOU, D. PERREA, N. NIKITEAS, D. DIMITROULIS (Athens, Greece; Aberdeen, UK; Cleveland, OH, USA). Anticancer Res 37:35-46, 2017.
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. J. POLIVKA JR, J. POLIVKA, L. HOLUBEC, T. KUBIKOVA, V. PRIBAN, O. HES, K.  PIVOVARCIKOVA, I. TRESKOVA (Plzen, Czech Republic).  Anticancer Res 37:21-34, 2017.
Three Pathways of Colonic Carcinogenesis in Rats. C.A. RUBIO (Stockholm, Sweden).  Anticancer Res 37:15-20, 2017.
Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes. D. MORIS, D. DIMITROULIS, S. VERNADAKIS, A. PAPALAMPROS, E. SPARTALIS, A. PETROU, T.M. PAWLIK, E.  FELEKOURAS (Cleveland; Columbus, OH, USA; Athens, Greece). Anticancer Res 37:9-14, 2017.
Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review. A.H. NGUYEN, S.Q. DETTY, D.K. AGRAWAL (Omaha, NE, USA). Anticancer Res 37:1-8, 2017.
Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-purposes with TGF-β/SMAD Signaling. S. SHANY, I. SIGAL-BATIKOFF, S. LAMPRECHT (Beersheva, Israel). Anticancer Res 36:6225-6234, 2016.
Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens. I. OKAZAKI, S. ISHIKAWA, W. ANDO, Y. SOHARA (Tokyo; Nasushiobara; Okegawa, Japan). Anticancer Res 36:6207-6224, 2016.
Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. F.E. BURONI, M.G. PERSICO, F. PASI, L. LODOLA, R. NANO, C. APRILE (Pavia, Italy). Anticancer Res 36:5719-5730, 2016.
Potential Anti-metastasis Natural Compounds for Lung Cancer. P. CHANVORACHOTE, S. CHAMNI, C. NINSONTIA, P.P. PHIBOONCHAIYANAN (Bangkok, Thailand).  Anticancer Res 36:5707-5717, 2016.
The Anticancer Activity of the Old Neuroleptic Phenothiazine-type Drug Thioridazine. G. SPENGLER, Á. CSONKA, J. MOLNÁR, L. AMARAL (Szeged, Hungary; Lisbon, Portugal). Anticancer Res 36:5701-5706, 2016.
Heart Peptide Hormones: Adjunct and Primary Treatments of Cancer. D.L. VESELY (Tampa, FL, USA). Anticancer Res 36:5693-5700, 2016.
Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment. B.R.B. PIRES, Í.S.S. DE AMORIM, L.D.E. SOUZA, J.A. RODRIGUES, A.L. MENCALHA (Rio de Janeiro, RJ, Brazil).  Anticancer Res 36:5681-5691, 2016.
Regulation of the Expression of Cytoplasmic Polyadenylation Element Binding Proteins for the Treatment of Cancer. Y. CHEN, Y.-H. TSAI, S.-H. TSENG (New Taipei; Taoyuan; Taipei, Taiwan, ROC).  Anticancer Res 36:5673-5680, 2016.
Identification of Important Compounds Isolated from Natural Sources that Have Activity Against Multidrug-resistant Cancer Cell Lines: Effects on Proliferation, Apoptotic Mechanism and the Efflux Pump Responsible for Multi-resistance Phenotype. L. AMARAL, G. SPENGLER, J. MOLNAR (Szeged, Hungary; Lisbon, Portugal). Anticancer Res 36:5665-5672, 2016.
The Antitumor Effect of Singlet Oxygen. G. BAUER (Freiburg, Germany). Anticancer Res 36:5649-5663, 2016.
Molecular Mechanisms of Anti-metastatic Activity of Curcumin. Y. DENG, E. VERRON, R. ROHANIZADEH (Sydney, Australia; Nantes, France). Anticancer Res 36:5639-5647, 2016.
Discovery of Anticancer Agents of Diverse Natural Origin. A.D. KINGHORN, E.J. CARCACHE DE BLANCO, D.M. LUCAS, H.L. RAKOTONDRAIBE, J. ORJALA, D.D. SOEJARTO, N.H. OBERLIES, C.J. PEARCE, M.C. WANI, B.R. STOCKWELL, J.E. BURDETTE, S.M. SWANSON, J.R. FUCHS, M.A. PHELPS, L. XU, X. ZHANG, Y.Y. SHEN (Columbus, OH; Chicago, IL; Greensboro; Hillsborough; Research Triangle Park, NC; New York, NY; Madison, WI; Andover, MA, USA). Anticancer Res 36:5623-5637, 2016.
Immune Blockade Inhibition in Breast Cancer. I.A. VOUTSADAKIS (Sudbury, ON, Canada).  Anticancer Res 36:5607-5622, 2016.
Cancer Immunology and Immunotherapy. A. SUKARI, M. NAGASAKA, A. AL-HADIDI, L.G. LUM (Detroit; Royal Oak, MI; Charlottesville, VA, USA). Anticancer Res 36:5593-5606, 2016.
Therapeutic Innovations for Targeting Hepatoblastoma. A. GARNIER, M. ILMER, R. KAPPLER, M. BERGER (Munich, Germany; Atlanta, GA, USA). Anticancer Res 36:5577-5592, 2016.
MicroRNAs: A Puzzling Tool in Cancer Diagnostics and Therapy. B. D’ANGELO, E. BENEDETTI, A. CIMINI, A. GIORDANO (Philadelphia, PA, USA; L’Aquila; Assergi; Siena, Italy). Anticancer Res 36:5571-5575, 2016.
Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. S. BOUSSIOS, G. ZARKAVELIS, E. SERAJ, I. ZERDES, K. TATSI, G. PENTHEROUDAKIS (Ioannina, Greece). Anticancer Res 36:5031-5042,2016.
Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors. M. CAPOZZI, C. VON ARX, C. DE DIVITIIS, A. OTTAIANO, F. TATANGELO, G.M. ROMANO, S. TAFUTO (Naples, Italy). Anticancer Res 36:5025-5030,2016.
Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Αgainst Medullary Thyroid Cancer? C. DAMASKOS, S. VALSAMI, E. SPARTALIS, E.A. ANTONIOU, P. TOMOS, S. KARAMAROUDIS, T. ZOUMPOU, V. PERGIALIOTIS, K. STERGIOS, C. MICHAELIDES, K. KONTZOGLOU, D. PERREA, N. NIKITEAS, D. DIMITROULIS (Athens, Greece; Harlow, UK).  Anticancer Res 36:5019-5024,2016.
Ageing as an Important Risk Factor for Cancer. K. SMETANA JR., L. LACINA, P. SZABO, B. DVOŘÁNKOVÁ, P. BROŽ, A. ŠEDO (Prague; Vestec, Czech Republic; Kosice, Slovak Republic).  Anticancer Res 36:5009-5017,2016.
Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma. T. HAYASHI, M. KAWANO, T. ICHIMURA, K. IDA, H. ANDO, D. ZHARHARY, Y. KANAI, H. ABURATANI, S. TONEGAWA, T. SHIOZAWA, N. YAEGASHI, I. KONISHI (Nagano; Chiba; Fukuoka; Osaka; Tokyo; Miyagi; Kyoto, Japan; Rehovot, Israel; Cambridge, MA, USA). Anticancer Res 36:4997-5007,2016.
Re-irradiation for Recurrent Primary Brain Tumors. C. NIEDER, N.H. ANDRATSCHKE, A.L. GROSU (Bodø; Tromsø, Norway; Zurich, Switzerland; Freiburg, Germany). Anticancer Res 36:4985-4995,2016
Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review. A.K.A. KARAGIANNIS, C. GIRIO-FRAGKOULAKIS, T. NAKOUTI (Athens, Greece; Nottingham, UK).  Anticancer Res 36:3803-3810,2016.
Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen. G.C.M. CEBINELLI, N.D.S. PEREIRA, M.M. SENA, C.E.C. DE OLIVEIRA, T.C. FUJITA, S.P.D. DA ROCHA, F.J.D.A. OLIVEIRA, P.C. MARINELLO, M.A.E. WATANABE (Londrina-Paraná, Brazil). Anticancer Res 36:3795-3802,2016.
The Role of FOXP3 in Human Cancers. Ł. SZYLBERG, D. KARBOWNIK, A. MARSZAŁEK (Torun; Poznan, Poland). Anticancer Res 36:3789-3794,2016.
Non-routine Tracers for PET Imaging of High-grade Glioma. G. FROSINA (Genoa, Italy). Anticancer Res 36:3253-3260,2016.
The Use of Complementary and Alternative Medicine in Scandinavia: A Review Article. J. NILSSON, M. KÄLLMAN, U. ÖSTLUND, G. HOLGERSSON, M. BERGQVIST, S. BERGSTRÖM (Gavle; Umea, Sweden). Anticancer Res 36:3243-3251,2016.
Current Status of Biological Therapies for the Treatment of Metastatic Melanoma. T. TANG, R. ELDABAJE, L. YANG (San Francisco, CA, USA). Anticancer Res 36:3229-3241,2016.
Sphingosine Kinase Inhibitors as Maintenance Therapy of Glioblastoma After Ceramide-Induced Response. L.A. SORDILLO, P.P. SORDILLO, L. HELSON (Quakertown, PA, USA). Anticancer Res 36:2085-2095,2016.
The NFĸB Signaling Pathway in Papillomavirus-induced Lesions: Friend or Foe? R.M. GIL DA COSTA, M.M.S.M. BASTOS, R. MEDEIROS, P.A. OLIVEIRA (Porto; Vila Real, Portugal). Anticancer Res 36:2073-2083,2016.
Methods to Increase Future Liver Remnant Volume in Patients with Primarily Unresectable Colorectal Liver Metastases: Current State and Future Perspectives. V. TRESKA (Pilsen, Czech Republic). Anticancer Res 36:2065-2071,2016.
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. A. GADDUCCI, M.E. GUERRIERI (Pisa, Italy). Anticancer Res 36:2055-2064,2016.
Page: 1 2 3 4 5 6 ... 7 8 9 10 
Custom Tables Plugin 05a1a29bdcae7b12229e651a9fd48b11

IMPORTANT NOTE: You may submit your article only through our online submission system